Brad E. Hoffman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Brad E. Hoffman has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Roland W. Herzog
Department of Pediatrics, University of Florida, Gainesville, FL, USA
19 shared publications Cox Terhorst
Division of Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
8 shared publications- Sushrusha Nayak
Department of Medicine, Karolinska Institute , Stockholm, Sweden
6 shared publications Roland W. Herzog
Department of Pediatrics, College of Medicine, University of Florida, Gainesville, FL, USA
5 shared publicationsDavid M. Markusic
Department of Pediatrics, Div. Cell and Molecular Therapy, University of Florida, United States
4 shared publicationsGeorge Q. Perrin
Department of Pediatrics, Division of Cellular and Molecular Therapy, University of Florida, Gainesville, FL, United States
4 shared publications
Latest Publications
- Open Access
- 27 December 2022
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 28, 177-189
Induction of antigen-specific tolerance by hepatic AAV immunotherapy regardless of T cell epitope usage or mouse strain background
- 27 December 2022
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 28, 177-189
Open AccessInduction of antigen-specific tolerance by hepatic AAV immunotherapy regardless of T cell epitope usage or mouse strain background
- 1 August 2019
- Published by Elsevier in Cellular Immunology
- Vol. 342, 103682
Regulatory T cells and TLR9 activation shape antibody formation to a secreted transgene product in AAV muscle gene transfer
- 1 August 2019
- Published by Elsevier in Cellular Immunology
- Vol. 342, 103682
Regulatory T cells and TLR9 activation shape antibody formation to a secreted transgene product in AAV muscle gene transfer
- 1 August 2019
- Published by Elsevier in Cellular Immunology
- Vol. 342, 103728
Liver induced transgene tolerance with AAV vectors
- 1 August 2019
- Published by Elsevier in Cellular Immunology
- Vol. 342, 103728
Liver induced transgene tolerance with AAV vectors
- Open Access
- 1 January 2018
- Published by Elsevier in Molecular Therapy
- Vol. 26 (1) , 173-183
Gene Therapy-Induced Antigen-Specific Tregs Inhibit Neuro-inflammation and Reverse Disease in a Mouse Model of Multiple Sclerosis
- 1 January 2018
- Published by Elsevier in Molecular Therapy
- Vol. 26 (1) , 173-183
Open AccessGene Therapy-Induced Antigen-Specific Tregs Inhibit Neuro-inflammation and Reverse Disease in a Mouse Model of Multiple Sclerosis
- 1 August 2017
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 57 (2) , 238-247
Alpha-1 Antitrypsin-Deficient Macrophages Have Increased Matriptase-Mediated Proteolytic Activity
Alpha-1 antitrypsin (AAT) deficiency–associated emphysema is largely attributed to insufficient inhibition of neutrophil elastase released from neutrophils. Correcting AAT levels using augmentation therapy only slows disease progression, and that suggests a more complex process of lung destruction. Because alveolar macrophages (Mɸ) express AAT, we propose that the expression and intracellular accumulation of mutated Z-AAT (the most common mutation) compromises Mɸ function and contributes to emphysema development. Extracellular matrix (ECM) degradation is a hallmark of emphysema pathology. In this study, Mɸ from individuals with Z-AAT (Z-Mɸ) have greater proteolytic activity on ECM than do normal Mɸ. This abnormal Z-Mɸ activity is not abrogated by supplementation with exogenous AAT and is likely the result of cellular dysfunction induced by intracellular accumulation of Z-AAT. Using pharmacologic inhibitors, we show that several classes of proteases are involved in matrix degradation by Z-Mɸ. Importantly, compared with normal Mɸ, the membrane-bound serine protease, matriptase, is present in Z-Mɸ at higher levels and contributes to their proteolytic activity on ECM. In addition, we identified matrix metalloproteinase (MMP)-14, a membrane-anchored metalloproteinase, as a novel substrate for matriptase, and showed that matriptase regulates the levels of MMP-14 on the cell surface. Thus, high levels of matriptase may contribute to increased ECM degradation by Z-Mɸ, both directly and through MMP-14 activation. In summary, the expression of Z-AAT in Mɸ confers increased proteolytic activity on ECM. This proteolytic activity is not rescued by exogenous AAT supplementation and could thus contribute to augmentation resistance in AAT deficiency–associated emphysema.
- 1 August 2017
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 57 (2) , 238-247
Alpha-1 Antitrypsin-Deficient Macrophages Have Increased Matriptase-Mediated Proteolytic Activity
Alpha-1 antitrypsin (AAT) deficiency–associated emphysema is largely attributed to insufficient inhibition of neutrophil elastase released from neutrophils. Correcting AAT levels using augmentation therapy only slows disease progression, and that suggests a more complex process of lung destruction. Because alveolar macrophages (Mɸ) express AAT, we propose that the expression and intracellular accumulation of mutated Z-AAT (the most common mutation) compromises Mɸ function and contributes to emphysema development. Extracellular matrix (ECM) degradation is a hallmark of emphysema pathology. In this study, Mɸ from individuals with Z-AAT (Z-Mɸ) have greater proteolytic activity on ECM than do normal Mɸ. This abnormal Z-Mɸ activity is not abrogated by supplementation with exogenous AAT and is likely the result of cellular dysfunction induced by intracellular accumulation of Z-AAT. Using pharmacologic inhibitors, we show that several classes of proteases are involved in matrix degradation by Z-Mɸ. Importantly, compared with normal Mɸ, the membrane-bound serine protease, matriptase, is present in Z-Mɸ at higher levels and contributes to their proteolytic activity on ECM. In addition, we identified matrix metalloproteinase (MMP)-14, a membrane-anchored metalloproteinase, as a novel substrate for matriptase, and showed that matriptase regulates the levels of MMP-14 on the cell surface. Thus, high levels of matriptase may contribute to increased ECM degradation by Z-Mɸ, both directly and through MMP-14 activation. In summary, the expression of Z-AAT in Mɸ confers increased proteolytic activity on ECM. This proteolytic activity is not rescued by exogenous AAT supplementation and could thus contribute to augmentation resistance in AAT deficiency–associated emphysema.
- Open Access
- 15 June 2017
- Published by American Society of Hematology in Blood
- Vol. 129 (24) , 3184-3195
Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8+ T cells
Key Points: Crosspriming of AAV capsid-specific CD8+ T cells requires cooperation between distinct subsets of DCs. Innate immune sensing of the viral DNA genome induces cross-presentation of viral capsid in trans.
- 15 June 2017
- Published by American Society of Hematology in Blood
- Vol. 129 (24) , 3184-3195
Open AccessPlasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8+ T cells
Key Points: Crosspriming of AAV capsid-specific CD8+ T cells requires cooperation between distinct subsets of DCs. Innate immune sensing of the viral DNA genome induces cross-presentation of viral capsid in trans.
- Open Access
- 1 April 2017
- Published by Elsevier in Molecular Therapy
- Vol. 25 (4) , 880-891
The Balance between CD8+ T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose
- 1 April 2017
- Published by Elsevier in Molecular Therapy
- Vol. 25 (4) , 880-891
Open AccessThe Balance between CD8+ T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose
- Open Access
- 1 June 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24 (6) , 1042-1049
Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid
- 1 June 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24 (6) , 1042-1049
Open AccessSuperior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid
- Open Access
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S35
79. Vector Dose Delineates Between Chronic, Non-Functional CD8+ T Cell Response and Tolerance to the Transgene Product Upon Liver Gene Transfer
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S35
Open Access79. Vector Dose Delineates Between Chronic, Non-Functional CD8+ T Cell Response and Tolerance to the Transgene Product Upon Liver Gene Transfer
- Open Access
- 1 February 2016
- Published by Elsevier in Biomaterials
- Vol. 80, 68-79
Low cost delivery of proteins bioencapsulated in plant cells to human non-immune or immune modulatory cells
- 1 February 2016
- Published by Elsevier in Biomaterials
- Vol. 80, 68-79
Open AccessLow cost delivery of proteins bioencapsulated in plant cells to human non-immune or immune modulatory cells